KING OF PRUSSIA, Pa. -- (BUSINESS WIRE) -- Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it will host a conference call on Friday, May 9, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2014.
The call can be accessed by dialing (855) 465-0180 (U.S. and Canada) or (484) 756-4313 (international), and entering passcode 36961657.
To access a live audio webcast of the presentation, please visit the “Investors” section at trevenainc.com. The webcast will be recorded and available for replay on the company's website for two weeks.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic - TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.